• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Genetic and physiological insights into satiation variability predict responses to obesity treatment.对饱腹感变异性的遗传和生理学见解可预测对肥胖治疗的反应。
Cell Metab. 2025 Jun 3. doi: 10.1016/j.cmet.2025.05.008.
2
Unraveling the Variability of Human Satiation: Implications for Precision Obesity Management.解析人类饱腹感的变异性:对精准肥胖管理的启示。
Res Sq. 2024 May 23:rs.3.rs-4402499. doi: 10.21203/rs.3.rs-4402499/v1.
3
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.肥胖症药物治疗与体重减轻及不良事件的关联:一项系统评价与荟萃分析。
JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602.
4
Long-term effects of weight-reducing drugs in people with hypertension.减肥药物对高血压患者的长期影响。
Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4.
5
Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.替尔泊肽与肥胖或超重成人的健康相关生活质量:SURMOUNT-3 三期随机试验结果
Diabetes Obes Metab. 2025 May 14. doi: 10.1111/dom.16463.
6
Calories to satiation-A new predictor of anti-obesity therapy outcome?饱腹感所需卡路里——抗肥胖治疗效果的新预测指标?
Cell Metab. 2025 Aug 5;37(8):1628-1629. doi: 10.1016/j.cmet.2025.07.003.
7
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
8
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.利拉鲁肽对肥胖患者体重、饱腹感和胃功能的影响:一项随机、安慰剂对照的初步试验。
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):890-899. doi: 10.1016/S2468-1253(17)30285-6. Epub 2017 Sep 27.
9
Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.与肥胖及减肥治疗反应相关的定量胃肠道和心理特征。
Gastroenterology. 2015 Mar;148(3):537-546.e4. doi: 10.1053/j.gastro.2014.11.020. Epub 2014 Dec 6.
10
Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.减肥药物对心脏代谢风险特征的影响:系统评价和网络荟萃分析。
Gastroenterology. 2018 Apr;154(5):1309-1319.e7. doi: 10.1053/j.gastro.2017.12.024. Epub 2018 Jan 3.

本文引用的文献

1
Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.享乐性进食由与胰高血糖素样肽-1受体饱腹感作用相对抗的多巴胺能神经元控制。
Science. 2025 Mar 28;387(6741):eadt0773. doi: 10.1126/science.adt0773.
2
Polygenic Score Approach to Predicting Risk of Metabolic Syndrome.预测代谢综合征风险的多基因评分方法
Genes (Basel). 2024 Dec 26;16(1):22. doi: 10.3390/genes16010022.
3
Dissociable hindbrain GLP1R circuits for satiety and aversion.饱腹感和厌恶感的可分离后脑 GLP1R 回路。
Nature. 2024 Aug;632(8025):585-593. doi: 10.1038/s41586-024-07685-6. Epub 2024 Jul 10.
4
GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans.GLP-1 通过小鼠和人类的下丘脑回路增加摄食前饱腹感。
Science. 2024 Jul 26;385(6707):438-446. doi: 10.1126/science.adj2537. Epub 2024 Jun 27.
5
Adaptive Effects of Endocrine Hormones on Metabolism of Macronutrients during Fasting and Starvation: A Scoping Review.禁食和饥饿期间内分泌激素对常量营养素代谢的适应性影响:一项范围综述
Metabolites. 2024 Jun 16;14(6):336. doi: 10.3390/metabo14060336.
6
Genetic risk score based on obesity-related genes and progression in weight loss after bariatric surgery: a 60-month follow-up study.基于肥胖相关基因的遗传风险评分与减重手术后体重减轻进展:一项 60 个月随访研究。
Surg Obes Relat Dis. 2024 Sep;20(9):814-821. doi: 10.1016/j.soard.2024.04.002. Epub 2024 Apr 6.
7
Obesity: A Review of Pathophysiology and Classification.肥胖症:病理生理学与分类综述。
Mayo Clin Proc. 2023 Dec;98(12):1842-1857. doi: 10.1016/j.mayocp.2023.05.026. Epub 2023 Oct 11.
8
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.GWAS 分析 476326 名个体的随机血糖水平,为糖尿病的病理生理学、并发症和治疗分层提供了新见解。
Nat Genet. 2023 Sep;55(9):1448-1461. doi: 10.1038/s41588-023-01462-3. Epub 2023 Sep 7.
9
Development and validation of an interpretable machine learning-based calculator for predicting 5-year weight trajectories after bariatric surgery: a multinational retrospective cohort SOPHIA study.基于可解释机器学习的预测减重手术后 5 年体重轨迹计算器的开发和验证:一项多中心回顾性队列 SOPHIA 研究。
Lancet Digit Health. 2023 Oct;5(10):e692-e702. doi: 10.1016/S2589-7500(23)00135-8. Epub 2023 Aug 29.
10
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.基于模型的方法预测超重或肥胖人群使用司美格鲁肽的个体减重情况。
Diabetes Obes Metab. 2023 Nov;25(11):3171-3180. doi: 10.1111/dom.15211. Epub 2023 Jul 9.

对饱腹感变异性的遗传和生理学见解可预测对肥胖治疗的反应。

Genetic and physiological insights into satiation variability predict responses to obesity treatment.

作者信息

Cifuentes Lizeth, Anazco Diego, O'Connor Timothy, Hurtado Maria Daniela, Ghusn Wissam, Campos Alejandro, Fansa Sima, McRae Alison, Madhusudhan Sunil, Kolkin Elle, Ryks Michael, Harmsen William S, Ciotlos Serban, Abu Dayyeh Barham K, Hensrud Donald D, Camilleri Michael, Acosta Andres

机构信息

Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Phenomix Sciences Inc, Menlo Park, CA, USA.

出版信息

Cell Metab. 2025 Jun 3. doi: 10.1016/j.cmet.2025.05.008.

DOI:10.1016/j.cmet.2025.05.008
PMID:40482646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12236147/
Abstract

Satiation, the process that regulates meal size and termination, varies widely among adults with obesity. To better understand and leverage this variability, we assessed calories to satiation (CTS) through an ad libitum meal, combined with physiological and behavioral evaluations, including calorimetry, imaging, blood sampling, and gastric emptying tests. Although factors like baseline characteristics, body composition, and hormone levels partially explain CTS variability, they leave substantial variability unaccounted for. To address this gap, we developed a machine-learning-assisted genetic risk score (CTS) to predict high CTS. In a randomized clinical trial, participants with high CTS or CTS achieved greater weight loss with phentermine-topiramate over 52 weeks, whereas those with low CTS or CTS responded better to liraglutide at 16 weeks in a separate trial. These findings highlight the potential of combining satiation measurements with genetic modeling to predict treatment outcomes and inform personalized strategies for obesity management.

摘要

饱腹感是调节进餐量和进餐结束的过程,在肥胖成年人中差异很大。为了更好地理解和利用这种变异性,我们通过随意进餐评估了饱腹感所需热量(CTS),并结合了生理和行为评估,包括量热法、成像、血液采样和胃排空测试。尽管基线特征、身体成分和激素水平等因素部分解释了CTS的变异性,但仍有很大一部分变异性无法解释。为了填补这一空白,我们开发了一种机器学习辅助的遗传风险评分(CTS)来预测高CTS。在一项随机临床试验中,高CTS或CTS的参与者在52周内使用苯丁胺-托吡酯实现了更大程度的体重减轻,而在另一项单独试验中,低CTS或CTS的参与者在16周时对利拉鲁肽反应更好。这些发现凸显了将饱腹感测量与遗传建模相结合以预测治疗结果并为肥胖管理提供个性化策略的潜力。